ArticlePharmacoEconomics2017
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
Min Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
68 papers cite itlatest 60 shown
this paperpooled ittrialcites it